Flare Frequency Associated With Reduced Quality of Life and Family Role Functioning in SLE
Lupus flares contributed to impaired functional and psychologic well-being, family functioning, and number of monthly healthy days.
Systemic Lupus Erythematosus
SYSTEMIC LUPUS ERYTHEMATOSUS
-
-
Voclosporin Granted Priority Review for Lupus Nephritis
The FDA will give Priority Review to the New Drug Application (NDA) of voclosporin for the treatment of lupus nephritis. -
Hydroxychloroquine During Pregnancy May Prevent Congenital Heart Block
For anti-SSA/Ro-positive mothers with a previous pregnancy complicated by congenital heart block (CHB), hydroxychloroquine may reduce the recurrence of CHB. -
Antibodies Against DNA Complexes Linked to Bacteriuria and Flares in Systemic Lupus Erythematosus
Investigators assessed whether curli/eDNA complexes induced an immune response in patients with systemic lupus erythematosus. -
Trial Investigating Ustekinumab for Systemic Lupus Erythematosus Discontinued
Janssen has decided to discontinue the phase 3 LOTUS study evaluating ustekinumab (Stelara®) for the treatment of systemic lupus erythematosus. -
SLE May Have Early Effect on Peripheral Nerve Function Before Electrophysiologic or Clinical Neuropathy Development
Researchers determined whether SLE could have an early effect on peripheral nerve function before the development of electrophysiologic abnormalities. -
Lack of EULAR/ERA-EDTA Response Predicts Chronic Kidney Disease in Patients With Lupus Nephritis
Researchers evaluated EULAR/ERA-EDTA response to therapy in patients with lupus nephritis. -
Inclusion of Non-Criteria Features to SLE Classification Improves Diagnostic Accuracy
Researchers identified criteria and non-criteria features associated with SLE, which can be used in classification criteria. -
Belimumab Plus Standard Lupus Nephritis Therapy Improves Renal Responses
Adding belimumab to standard therapy for lupus nephritis is associated with better renal outcomes compared with standard therapy alone. -
Voclosporin NDA for Lupus Nephritis Submitted to the FDA
The NDA for voclosporin has been submitted to the Food and Drug Administration (FDA) for the treatment for lupus nephritis.
LATEST NEWS
Blood Pressure Dipping May Be a Marker of Cardiovascular Function in Pediatric-Onset SLE
Researchers evaluated blood pressure dipping as a marker of endothelial function and subclinical atherosclerosis in pediatric-onset systemic lupus erythematosus.
Interferon Inhibition With Anifrolumab Reduces Disease Activity in Systemic Lupus Erythematosus
An investigational type 1 interferon receptor inhibitor was associated with significant reduction in disease activity in patients with systemic lupus erythematosus.
High Serum Albumin Levels Have a Protective Effect on Mental Health in Patients With Juvenile SLE
Study findings from EULAR 2020 suggest that higher albumin levels provide a potentially protective effect on mental health in juvenile SLE.
Genetic Data May Increase Diagnostic Efficiency for Rheumatic Disease
Converting genotype information into an interpretable probability value for five different inflammatory arthritis-causing diseases could potentially improve the diagnostic efficiency of rheumatic disease.
Considerations for Hydroxychloroquine Use in Patients With Diabetes
Careful consideration should be taken before using hydroxychloroquine in patients with diabetes, particularly in the context of COVID-19.
WHO Suspends Testing of Hydroxychloroquine in Patients With COVID-19
The WHO has suspended use of the antimalarial drug hydroxychloroquine in a clinical trial of treatments of COVID-19 after a study revealed that patients taking the drug are at increased risk for death and serious heart problems.
Hydroxychloroquine Does Not Improve COVID-19 Pneumonia Outcomes
Hydroxychloroquine does not improve outcomes in COVID-19.
Ocular Complications Common Across Spectrum of Rheumatic Diseases
Between one-fifth and one-third of patients with rheumatoid arthritis, connective tissue disease, and vasculitis have ocular complications.
ACP Advises Against Chloroquine, Hydroxychloroquine Use for COVID-19
In a special article from the American College of Physicians, practice points are presented to guide the use of chloroquine or hydroxychloroquine in the setting of COVID-19.
Lesser Damage Accrual Among Patients Not Fulfilling the 2019 EULAR/ACR Criteria for SLE
Investigators determined the difference in outcomes in patients who achieved or did not achieve the 2019 EULAR/ACR criteria for SLE.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Systemic Lupus Erythematosus
